Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

ne-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or rev
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Argos Therapeutics announced today that interleukin ... dendritic cell (DC) immunotherapy and can be used as a ... company,s lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). ... Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated ...
... Rotational molder REMCON Plastics is already seeing process reduction ... organized under the leadership of new hire Benjamin F. ... REMCON,s Lean Manufacturing and Continuous Improvement Initiatives. He will ... active teams to sustain a strong, lean culture within ...
Cached Medicine Technology:Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 2Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 3Six Sigma Black Belt and Lean Sensei Ben Wittich Joins REMCON Plastics 2
(Date:4/21/2014)... policymakers consider ways to ease prohibitions on marijuana, the ... over the past century may provide valuable lessons, according ... that legalized marijuana in Colorado and Washington for recreational ... how to best allow the production, sales and the ... related social ills. , A new study published online ...
(Date:4/20/2014)... Researchers may have identified key genes linked to why ... others, according to a study released today that will ... Annual Meeting in Philadelphia, April 26 to May 3, ... it provides an objective way to understand pain and ... study author Tobore Onojjighofia, MD, MPH, with Proove Biosciences ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
Breaking Medicine News(10 mins):Health News:Regulating legal marijuana could be guided by lessons from alcohol and tobacco, study says 2Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2
... that only 2 in 5 seek any assistance, ... being,one of today,s most common disorders, it is regularly ... occasional feelings of anxiety -- muscle tension,headache, nausea, fatigue, ... speaking, first dates, or during times of stress such ...
... Diseases (NIAID), part of the National Institutes of ... Clinical Proteomics Centers for Infectious Diseases and Biodefense. ... Texas Medical Branch (UTMB), Galveston, and to the ... centers will analyze human blood and other tissue ...
... launch anticipated in early 2009 -, CORONA, ... WPI ), a leading specialty pharmaceutical,company, announced today ... approved RAPAFLO(TM) (silodosin), the company,s new alpha blocker ... BPH., BPH is the number one reason ...
... Celestial,Group, Inc. (Nasdaq: HAIN ), a leading ... today announced that Irwin Simon, President and,Chief Executive ... the,Company on Wednesday, October 15, 2008 at the ... http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ), The investor presentation ...
... Robbins & Myers, Inc.,(NYSE: RBN ) ... a regular,cash dividend payment of $0.0375 per share. ... shareholders of record as of October 20, 2008., ... supplier of engineered equipment and,systems for critical applications ...
... Oct. 8 New physical activity guidelines,released today ... Services (HHS),will give Americans the information they need ... of the USA, the national resource office for ... Activity Guidelines for Americans set achievable,goals for everyone ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:NIAID awards contracts to search for protein markers of disease 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 4Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:YMCA of the USA Supports New National Physical Activity Guidelines 2
Double-ended. Designated most popular model or size....
Designated most popular model or size. 3 mm tip....
Octagonal handle. 3 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: